PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS

PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS

Objectives. To provide a pharmacoeconomic analysis of brentuximab vetodin therapy in relapsed or refractory CD30+ systemic anaplastic large-cell lymphoma in patients over 18 years of age.Methods. Recommendations to carry out a budget impact analysis in theRussian Federation (2016) were used.Results....

Full description

Saved in:

Bibliographic Details
Main Authors:	A. S. Kolbin, I. A. Vilum, М. A. Proskurin, Yu. E. Balykina
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2017-05-01
Series:	Фармакоэкономика
Subjects:	brentuximab vetodin relapsed or refractory cd30+ systemic anaplastic large cell lymphoma pharmacoeconomics budget impact analysis list of vital and essential drugs
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/181
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
by: Margaret Hux, et al.
Published: (2016-10-01)

Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti‐CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma
by: Yian Zhang, et al.
Published: (2025-08-01)

Modern approaches to the treatment of relapsed follicular lymphoma
by: Yu. E. Ryabukhina, et al.
Published: (2022-07-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study
by: A. S. Kolbin, et al.
Published: (2023-11-01)

RATIONAL PHARMACOTHERAPY BASED ON PHARMACOECONOMIC DATA AUDIT: PRINCIPLES AND APPLICATION IN BULGARIA
by: T. Vekov
Published: (2015-09-01)

Comparative clinical and economic assessment of polatuzumab vedotin therapy in combination with bendamustine and rituximab for adult transplantation-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma
by: I. N. Dyakov, et al.
Published: (2022-07-01)

Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen
by: Andrew Whiteley, et al.
Published: (2025-05-01)

Pharmacoeconomic analysis in various nosologies
by: A. A. Svistunov, et al.
Published: (2016-06-01)

FLAG with Bortezomib in Children and Adolescents with Relapsed/Refractory Acute Myeloid Leukemia in a Resource-Limited Setting: A Single-Center Experience from India
by: Dipesh Dave, et al.

Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma—importance of pre-CAR-T optimization
by: Phoebe Joy Ho, et al.
Published: (2025-08-01)

Elotuzumab in the treatment of patients with refractory and relapsed multiple myeloma Experience of the Lapino Clinical Hospital Oncohematology Department
by: Yu. E. Ryabukhina, et al.
Published: (2023-12-01)

BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD
by: A. S. Kolbin, et al.
Published: (2015-06-01)

PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA
by: A. V. Pavlysh, et al.
Published: (2015-03-01)

X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL
by: Michela Carlet, et al.
Published: (2022-11-01)

A case report of relapsed and refractory multiple myeloma with multifocal extramedullary infiltration and pulmonary adenocarcinoma
by: DU Fang, et al.
Published: (2025-01-01)

Targeted therapy of anaplastic thyroid cancer
by: P. A. Nikiforovich, et al.
Published: (2023-03-01)

Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review
by: Mei Zhou, et al.
Published: (2025-07-01)

Pharmacoeconomic effectiveness of phytotherapy in complex treatment of pyelonephritis
by: V. V. Ivanov, et al.
Published: (2015-04-01)

Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies
by: Allison M. Bock, et al.
Published: (2025-07-01)

CYP2D6 genotyping in the daily routine of a psychiatric hospital – pharmacoeconomic evaluation
by: A. A. Kurylev, et al.
Published: (2018-05-01)

REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS
by: Andrey Vladislavovich Pavlysh, et al.
Published: (2015-09-01)

PHARMACOEPIDEMIOLOGICAL AND PHARMACOECONOMIC STUDIES OF ANTIHYPERTENSIVE TREATMENT IN RUSSIA. Analytical Review
by: T. S. Romanenko, et al.
Published: (2015-09-01)

Systemic therapy for anaplastic thyroid cancer: a literature review
by: E. S. Dzhelialov, et al.
Published: (2025-01-01)

PHARMACOECONOMIC ANALYSIS OF MARKET OF BIOLOGICALLY ACTIVE ADDITIVES MERCHANDIZED IN PHARMACY ORGANIZATIONS
by: O. V. Belousova, et al.
Published: (2015-12-01)

Efficacy and safety of R-GemOx regimen for relapsed refractory B-cell lymphoma: a single-arm Meta analysis
by: Guo-Xin HUANG, et al.
Published: (2023-12-01)

Anaplastic thyroid cancer: current state of the problem
by: P. A. Nikiforovich, et al.
Published: (2025-05-01)

PHARMACOECONOMIC ANALYSIS OF ANTIHYPERTENSIVE DRUG COMBINATIONS USE
by: E. I. Tarlovskaya, et al.
Published: (2015-09-01)

PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION
by: V. A. Chibilyaev, et al.
Published: (2015-03-01)

Combination therapy of TKIs and ICIs for the treatment of anaplastic thyroid carcinoma
by: Xi Zhang, et al.
Published: (2025-05-01)

Inotuzumab Ozogamicin as a Bridge to Stem Cell Transplantation in Relapsed Pediatric BCP‐ALL After Tisagenlecleucel: A Case Series
by: Margo Aertgeerts, et al.
Published: (2025-03-01)

Cascade-penetrating domino-ferroptosis nano inducer synergizes with sonodynamic therapy for anaplastic thyroid cancer
by: Peng Dong, et al.
Published: (2025-10-01)

CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis
by: Jing Shen, et al.
Published: (2025-08-01)

Extranodal testicular anaplastic versus plasmablastic plasma cell tumor: A rare case with diagnostic dilemma in a developing country
by: P. Jovita M. Martin, et al.
Published: (2011-01-01)

Evaluation of conditional survival outcomes in patients with redefined anaplastic thyroid carcinoma
by: Yinuo Zheng, et al.
Published: (2025-06-01)

Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma
by: Carmen Tsang, et al.
Published: (2025-07-01)

PHARMACOECONOMICS AS A NEW INSTRUMENT OF PHARMACEUTICAL MARKETING
by: M. V. Protsenko, et al.
Published: (2015-03-01)

Exploring what matters most to patients in relapsed refractory multiple myeloma treatment: a Canadian discrete choice experiment with patients, caregivers and physicians
by: Rebekah Hall, et al.
Published: (2025-07-01)